stoxline Quote Chart Rank Option Currency Glossary
Harrow Health, Inc. (HROW)
18.25  0.16 (0.88%)    06-12 16:00
Open: 18.42
High: 19.12
Volume: 255,494
Pre. Close: 18.09
Low: 18.09
Market Cap: 646(M)
Technical analysis
2024-06-12 4:22:42 PM
Short term     
Mid term     
Targets 6-month :  22.33 1-year :  26.08
Resists First :  19.12 Second :  22.33
Pivot price 17.82
Supports First :  13.53 Second :  10.07
MAs MA(5) :  18.04 MA(20) :  17.47
MA(100) :  12.39 MA(250) :  13.69
MACD MACD :  1.2 Signal :  1.4
%K %D K(14,3) :  70.9 D(3) :  72.1
RSI RSI(14): 67.9
52-week High :  22.62 Low :  7.59
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HROW ] has closed below upper band by 22.4%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 19.14 - 19.21 19.21 - 19.27
Low: 17.9 - 17.99 17.99 - 18.06
Close: 18.12 - 18.25 18.25 - 18.36
Company Description

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Headline News

Wed, 29 May 2024
D.A. Davidson & CO. Grows Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Tue, 14 May 2024
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript - Seeking Alpha

Mon, 13 May 2024
HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024 - InvestorPlace

Thu, 02 May 2024
Harrow: Merits A Buy On Sales Potential (NASDAQ:HROW) - Seeking Alpha

Thu, 21 Mar 2024
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript - Yahoo Finance

Tue, 19 Mar 2024
Harrow Health Inc Unveils Investor Presentation Update - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 35 (M)
Shares Float 27 (M)
Held by Insiders 14 (%)
Held by Institutions 60.1 (%)
Shares Short 4,980 (K)
Shares Short P.Month 5,920 (K)
Stock Financials
EPS -0.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.71
Profit Margin -22.6 %
Operating Margin -20.1 %
Return on Assets (ttm) -1.8 %
Return on Equity (ttm) -76.7 %
Qtrly Rev. Growth 32.5 %
Gross Profit (p.s.) 0
Sales Per Share 3.91
EBITDA (p.s.) 0.11
Qtrly Earnings Growth 0 %
Operating Cash Flow 7 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -20.06
PEG Ratio -2.3
Price to Book value 10.67
Price to Sales 4.65
Price to Cash Flow 86.9
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android